{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T03:31:54Z","timestamp":1783049514478,"version":"3.54.6"},"reference-count":51,"publisher":"Elsevier BV","issue":"21","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"am","delay-in-days":383,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.vaccine.2024.07.041","type":"journal-article","created":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T01:19:15Z","timestamp":1721438355000},"page":"126140","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Evaluation of combination vaccines targeting transmission of Plasmodium falciparum and P. vivax"],"prefix":"10.1016","volume":"42","author":[{"given":"Yi","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clifford T.H.","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maisa da Silva","family":"Araujo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhai K.","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice Oliveira","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jansen Fernandes","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8344-2004","authenticated-orcid":false,"given":"Joseph","family":"Vinetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0358-4924","authenticated-orcid":false,"given":"Nirbhay","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2024.07.041_b0005","unstructured":"World malaria report 2023. Geneva: World Health Organization;2023."},{"key":"10.1016\/j.vaccine.2024.07.041_b0010","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0140-6736(19)31096-7","article-title":"Mapping the global endemicity and clinical burden of Plasmodium vivax, 2000\u201317: a spatial and temporal modelling study","volume":"394","author":"Battle","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2024.07.041_b0015","doi-asserted-by":"crossref","first-page":"e0007140","DOI":"10.1371\/journal.pntd.0007140","article-title":"Growing evidence of Plasmodium vivax across malaria-endemic Africa","volume":"13","author":"Twohig","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2024.07.041_b0020","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1128\/CMR.00074-12","article-title":"Evidence and implications of mortality associated with acute Plasmodium vivax malaria","volume":"26","author":"Baird","year":"2013","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2024.07.041_b0025","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1086\/599041","article-title":"Vivax malaria: a major cause of morbidity in early infancy","volume":"48","author":"Poespoprodjo","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2024.07.041_b0030","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1371\/journal.pmed.0050127","article-title":"Plasmodium vivax and mixed infections are associated with severe malaria in children: a prospective cohort study from Papua New Guinea","volume":"5","author":"Genton","year":"2008","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2024.07.041_b0035","doi-asserted-by":"crossref","first-page":"e0010760","DOI":"10.1371\/journal.pntd.0010760","article-title":"Co-infection of the four major Plasmodium species: effects on densities and gametocyte carriage","volume":"16","author":"Holzschuh","year":"2022","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2024.07.041_b0040","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(23)02511-4","article-title":"Safety and efficacy of malaria vaccine candidate R21\/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial","volume":"403","author":"Datoo","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2024.07.041_b0045","doi-asserted-by":"crossref","DOI":"10.1172\/JCI156588","article-title":"RTS, S: the first malaria vaccine","volume":"132","author":"Zavala","year":"2022","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2024.07.041_b0050","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41541-020-0196-3","article-title":"Malaria vaccines since 2000: progress, priorities, products","volume":"5","author":"Duffy","year":"2020","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2024.07.041_b0055","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1080\/14760584.2024.2369583","article-title":"Immune mechanisms targeting malaria transmission: opportunities for vaccine development","volume":"23","author":"Bansal","year":"2024","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2024.07.041_b0060","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/14760584.2021.1878028","article-title":"Transmission-Blocking Vaccines: harnessing Herd Immunity for Malaria Elimination","volume":"20","author":"Duffy","year":"2021","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2024.07.041_b0065","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/bs.apar.2015.04.001","article-title":"Development of malaria transmission-blocking vaccines: from concept to product","volume":"89","author":"Wu","year":"2015","journal-title":"Adv Parasitol"},{"key":"10.1016\/j.vaccine.2024.07.041_b0070","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1365-3024.1990.tb00990.x","article-title":"Properties of epitopes of Pfs 48\/45, a target of transmission blocking monoclonal antibodies, on gametes of different isolates of Plasmodium falciparum","volume":"12","author":"Carter","year":"1990","journal-title":"Parasite Immunol"},{"key":"10.1016\/j.vaccine.2024.07.041_b0075","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/263057a0","article-title":"Malaria transmission blocked by immunisation with gametes of the malaria parasite","volume":"263","author":"Carter","year":"1976","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2024.07.041_b0080","doi-asserted-by":"crossref","first-page":"e2636","DOI":"10.1371\/journal.pone.0002636","article-title":"Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51","volume":"3","author":"Wu","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2024.07.041_b0085","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1016\/j.vaccine.2004.12.019","article-title":"Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria","volume":"23","author":"Malkin","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.07.041_b0090","doi-asserted-by":"crossref","first-page":"e0163144","DOI":"10.1371\/journal.pone.0163144","article-title":"Safety and Immunogenicity of Pfs25-EPA\/Alhydrogel\u00ae, a Transmission Blocking Vaccine against Plasmodium falciparum: an Open Label Study in Malaria Na\u00efve Adults","volume":"11","author":"Talaat","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2024.07.041_b0095","doi-asserted-by":"crossref","first-page":"19913","DOI":"10.1074\/jbc.M116.732305","article-title":"Structural and immunological characterization of recombinant 6-cysteine domains of the plasmodium falciparum sexual stage protein Pfs230","volume":"291","author":"MacDonald","year":"2016","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2024.07.041_b0100","doi-asserted-by":"crossref","DOI":"10.1128\/CVI.00140-17","article-title":"N-Terminal Pfs230 domain produced in baculovirus as a biological active transmission-blocking vaccine candidate","volume":"24","author":"Lee","year":"2017","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2024.07.041_b0105","doi-asserted-by":"crossref","unstructured":"Rausch KM, Barnafo EK, Lambert LE, Muratova O, Gorres JP, Anderson C, et al. Preclinical evaluations of Pfs25-EPA and Pfs230D1-EPA in AS01 for a vaccine to reduce malaria transmission. iScience. 2023;26:107192.","DOI":"10.1016\/j.isci.2023.107192"},{"key":"10.1016\/j.vaccine.2024.07.041_b0110","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/S1473-3099(23)00276-1","article-title":"Malaria transmission-blocking vaccines Pfs230D1-EPA and Pfs25-EPA in Alhydrogel in healthy Malian adults; a phase 1, randomised, controlled trial","volume":"23","author":"Sagara","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2024.07.041_b0115","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/j.vaccine.2012.01.003","article-title":"Plasmodium vivax gametocyte protein Pvs230 is a transmission-blocking vaccine candidate","volume":"30","author":"Tachibana","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.07.041_b0120","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41541-021-00383-8","article-title":"Preclinical development of a Pfs230-Pfs48\/45 chimeric malaria transmission-blocking vaccine","volume":"6","author":"Singh","year":"2021","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2024.07.041_b0125","doi-asserted-by":"crossref","DOI":"10.4269\/ajtmh.21-1320","article-title":"40 Years of Pfs48\/45 research as a transmission-blocking vaccine target of plasmodium falciparum malaria","author":"Sauerwein","year":"2022","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2024.07.041_b0130","doi-asserted-by":"crossref","first-page":"170","DOI":"10.2174\/156652321403140819122538","article-title":"Improving DNA vaccine performance through vector design","volume":"14","author":"Williams","year":"2014","journal-title":"Curr Gene Ther"},{"key":"10.1016\/j.vaccine.2024.07.041_b0135","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1128\/IAI.67.4.1688-1693.1999","article-title":"Immunization of mice with DNA-based Pfs25 elicits potent malaria transmission-blocking antibodies","volume":"67","author":"Lobo","year":"1999","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2024.07.041_b0140","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.vaccine.2007.10.066","article-title":"Markedly enhanced immunogenicity of a Pfs25 DNA-based malaria transmission-blocking vaccine by in vivo electroporation","volume":"26","author":"LeBlanc","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.07.041_b0145","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1128\/CVI.00185-15","article-title":"Evaluation of the impact of codon optimization and N-linked glycosylation on functional immunogenicity of Pfs25 DNA vaccines delivered by in vivo electroporation in preclinical studies in mice","volume":"22","author":"Datta","year":"2015","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2024.07.041_b0150","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.vaccine.2016.11.072","article-title":"Immunogenicity and malaria transmission reducing potency of Pfs48\/45 and Pfs25 encoded by DNA vaccines administered by intramuscular electroporation","volume":"35","author":"Datta","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.07.041_b0155","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1128\/IAI.72.1.253-259.2004","article-title":"Induction of Plasmodium falciparum transmission-blocking antibodies in nonhuman primates by a combination of DNA and protein immunizations","volume":"72","author":"Coban","year":"2004","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2024.07.041_b0160","doi-asserted-by":"crossref","first-page":"7049","DOI":"10.1016\/j.vaccine.2017.10.042","article-title":"Comparative functional potency of DNA vaccines encoding Plasmodium falciparum transmission blocking target antigens Pfs48\/45 and Pfs25 administered alone or in combination by in vivo electroporation in rhesus macaques","volume":"35","author":"Datta","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.07.041_b0165","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1016\/j.vaccine.2013.05.006","article-title":"Functional evaluation of malaria Pfs25 DNA vaccine by in vivo electroporation in olive baboons","volume":"31","author":"Kumar","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.07.041_b0170","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41541-022-00577-8","article-title":"mRNA-LNP expressing PfCSP and Pfs25 vaccine candidates targeting infection and transmission of Plasmodium falciparum","volume":"7","author":"Hayashi","year":"2022","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2024.07.041_b0175","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/s41541-023-00786-9","article-title":"A Pvs25 mRNA vaccine induces complete and durable transmission-blocking immunity to Plasmodium vivax","volume":"8","author":"Kunkeaw","year":"2023","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2024.07.041_b0180","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41541-023-00783-y","article-title":"mRNA vaccines expressing malaria transmission-blocking antigens Pfs25 and Pfs230D1 induce a functional immune response","volume":"9","author":"Scaria","year":"2024","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2024.07.041_b0185","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1016\/j.vaccine.2003.11.060","article-title":"Potent immunogenicity of DNA vaccines encoding Plasmodium vivax transmission-blocking vaccine candidates Pvs25 and Pvs28-evaluation of homologous and heterologous antigen-delivery prime-boost strategy","volume":"22","author":"Kongkasuriyachai","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.07.041_b0190","article-title":"Effective functional immunogenicity of a DNA vaccine combination delivered via in vivo electroporation targeting malaria infection and transmission","volume":"10","author":"Cao","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2024.07.041_b0195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158212","article-title":"Immunological cross-reactivity between malaria vaccine target antigen P48\/45 in plasmodium vivax and P. falciparum and cross-boosting of immune responses","volume":"11","author":"Cao","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2024.07.041_b0200","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/imm.12621","article-title":"Reduced immunogenicity of Plasmodium falciparum gamete surface antigen (Pfs48\/45) in mice after disruption of disulphide bonds - evaluating effect of interferon-\u03b3-inducible lysosomal thiol reductase","volume":"148","author":"Merino","year":"2016","journal-title":"Immunology"},{"key":"10.1016\/j.vaccine.2024.07.041_b0205","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1128\/IAI.01438-13","article-title":"Potent malaria transmission-blocking antibody responses elicited by Plasmodium falciparum Pfs25 expressed in Escherichia coli after successful protein refolding","volume":"82","author":"Kumar","year":"2014","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2024.07.041_b0210","doi-asserted-by":"crossref","first-page":"e6352","DOI":"10.1371\/journal.pone.0006352","article-title":"A potent malaria transmission blocking vaccine based on codon harmonized full length Pfs48\/45 expressed in Escherichia coli","volume":"4","author":"Chowdhury","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2024.07.041_b0215","doi-asserted-by":"crossref","DOI":"10.1128\/iai.00374-23","article-title":"Transmission-reducing and -enhancing monoclonal antibodies against Plasmodium vivax gamete surface protein Pvs48\/45","author":"Bansal","year":"2024","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2024.07.041_b0220","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s12936-022-04204-8","article-title":"Evaluation of sustainable susceptibility to Plasmodium vivax infection among colonized Anopheles darlingi and Anopheles deaneorum","volume":"21","author":"Santos","year":"2022","journal-title":"Malar J"},{"key":"10.1016\/j.vaccine.2024.07.041_b0225","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiae102","article-title":"A novel ex vivo assay to evaluate functional effectiveness of Plasmodium vivax transmission blocking vaccine using Pvs25 transgenic P. berghei","author":"Cao","year":"2024","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2024.07.041_b0230","doi-asserted-by":"crossref","DOI":"10.3791\/61426-v","article-title":"Plasmodium falciparum gametocyte culture and mosquito infection through artificial membrane feeding","author":"Tripathi","year":"2020","journal-title":"Journal of visualized experiments: JoVE"},{"key":"10.1016\/j.vaccine.2024.07.041_b0235","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.vaccine.2015.03.008","article-title":"Plasmodium vivax gametocyte proteins, Pvs48\/45 and Pvs47, induce transmission-reducing antibodies by DNA immunization","volume":"33","author":"Tachibana","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.07.041_b0240","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1365-3024.1994.tb00302.x","article-title":"Plasmodium falciparum malaria transmission-blocking immunity under conditions of low endemicity as in Sri Lanka","volume":"16","author":"Premawansa","year":"1994","journal-title":"Parasite Immunol"},{"key":"10.1016\/j.vaccine.2024.07.041_b0245","doi-asserted-by":"crossref","first-page":"26","DOI":"10.4269\/ajtmh.1988.39.26","article-title":"Monoclonal and polyclonal antibodies both block and enhance transmission of human Plasmodium vivax malaria","volume":"39","author":"Peiris","year":"1988","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2024.07.041_b0250","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.pt.2018.11.003","article-title":"Two-faced immunity? the evidence for antibody enhancement of malaria transmission","volume":"35","author":"Stone","year":"2019","journal-title":"Trends Parasitol"},{"key":"10.1016\/j.vaccine.2024.07.041_b0255","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.actatropica.2016.07.023","article-title":"Prevalence of Plasmodium falciparum transmission reducing immunity among primary school children in a malaria moderate transmission region in Zimbabwe","volume":"163","author":"Paul","year":"2016","journal-title":"Acta Trop"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2400803X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2400803X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T20:47:36Z","timestamp":1728506856000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2400803X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":51,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S0264410X2400803X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.07.041","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of combination vaccines targeting transmission of Plasmodium falciparum and P. vivax","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.07.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"126140"}}